EZZ Life Science reports strong financial performance
EZZ Life Science Holdings Limited (ASX:EZZ), a genomic life science company focused on improving the quality of life and human health, has reported a strong financial performance for the quarter ending on March 31, 2023 - resulting in the company share price jumping 38% before close yesterday afternoon.
The share price is up another 12% today.
EZZ announced cash receipts from customers totalling $11.2 million, a 30% increase from the previous quarter and a remarkable 182% increase compared to the same period last year.
Operating cash flows also surged, rising 371% from the previous quarter to $2.8 million. EZZ's cash position remained strong at $12.3 million at the end of the quarter, an increase of around $2.7 million compared to the previous quarter. The trading restriction on EZZ's 30 million shares was lifted in March 2023, including the two substantial shareholders Macquarie Holdings Pty Ltd and JNJ Mok Pty Ltd.
EZZ's omnichannel distribution capabilities were also expanded in the quarter, with the company establishing a presence on three new e-commerce platforms including Amazon Australia, eBay Australia, and Pinduoduo China. These online marketplaces provide EZZ with access to a wider customer base and the potential for increased sales.
The company also made significant progress in product innovation, releasing four new core products and two non-core products during the quarter. These included EZZ Children's Eye Health, EZZ Magnesium Plus, EZZ Sugar Metabolism, EZZ Liver Detox, EZZ Hair Protector, and EZZ Complexion Refresh.
EZZ signed an agreement with the University of Auckland, New Zealand, for a second ground-breaking anti-aging and immune-stimulation study during the quarter. The project commenced in January 2023 and will conclude with a final report due on 20 January 2026.
In February 2023, EZZ entered into a tripartite agreement with leading multinational pharmaceutical companies GMP Pharmaceuticals and Natural Innovations Group, with an aim to bring new wellness innovation solutions to market. The partnership is driven by a shared passion to improve the health and wellbeing of individuals, with a goal to extend lifespan and promote genetic longevity.
EAORON, EZZ's subsidiary, announced the launch of an updated product line to be stocked in Chemist Warehouse stores across Australia. The launch includes six new products, including the Hyaluronic Acid Glutathione Essence Face Mask and Hyaluronic Acid Glutathione Essence, and an upgrade to its one-of-a-kind product EAORON HA Collagen Essence V. This partnership will make EAORON's products more accessible to consumers, with 350 Chemist Warehouse stores across Australia to stock the upgraded product line. Additionally, EAORON's updated line of products will also be available through Chemist Warehouse's online store.
Overall, EZZ's strong financial performance and continued expansion in product innovation and distribution capabilities highlight the company's commitment to improving the quality of life and human health. The company's progress in research and development, strategic partnerships, and omnichannel distribution will likely position it well for long-term growth and success.
